This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceuticalcompanies. The evolution of value in healthcare is a trend that has important implications for communications, particularly because ‘value’ is very much in the eye of the beholder.
The COVID-19 pandemic kickstarted a period of profound change in how the pharmaceutical industry approaches both communications and commercialisation. The pharma company’s senior vice president for major markets talks about the continued evolution of the industry’s approach to communications and commercialisation.
There is little doubt that the arrival of COVID-19 changed the game for communication and commercialisation efforts for pharmaceuticalcompanies around the world. Today’s pharmaceutical ads have come a long way since the days of snake oil and miracle elixirs. Inside the colourful history of pharma advertising.
COVID-19 might have forced pharma to finally fully embrace digital communications, but that doesn’t mean the industry is good at using these platforms yet. Ian Daley and Jonathan Macdonald from EPG Health tell us how pharma can take cues from companies like Amazon. Responding to dynamic shifts in value communications.
In one of the fierier remarks from the roundtable, RFK Jr said: “At every level, doctors, other providers, our hospitals, the pharmaceuticalcompanies, the insurance companies, all make money by keeping us sick. We may still continue to send you service-related and other non-promotional communications.
In the fast-paced, highly competitive pharmaceutical industry, sales reps must adapt to new ways of engaging with customers and healthcare professionals (HCPs).
Communication between European Union (EU) member states is ongoing to finalise the details of the legislation, but at its core, the EHDS will provide a single registry of patient data from across the continent. Trust is something that you earn, so how we communicate what’s coming out of this directive is very important.
Physicians, patients, and caregivers are all tapping into the power of social media to communicate with one another and increase awareness about certain issues that are important to them. There are numerous benefits for pharmaceuticalcompanies in the healthcare influencer space.
Large pharmaceuticalcompanies such as AbbVie, Lilly, Roche and Takeda have demonstrated strong interest in licensing innovator oligonucleotides for CNS indications, accounting for 63% of licensing deals between 2021 and 2025 year-to-date. Can pharma tariffs “Make America Manufacture Again”? ASOs accounted for more than half ($3.54
A common theme heard from the advocacy groups AXON works with is “Nothing for us without us,” says Natalie Turner, director at AXON, a global healthcare communications agency. A lot of pharmaceuticalcompanies are trying to get their heads around how to include patients in the conversation,” says Natalie. Is pharma listening?
By GlobalData Learn more about Strategic Intelligence In light of the approvals of Leqembi and Kisunla, large pharmaceuticalcompanies are increasingly investing in Alzheimer’s disease through high-value acquisitions. Can pharma tariffs “Make America Manufacture Again”? Stay proactive with real-time data and expert analysis.
A data-driven strategy is essential to successfully communicate a brand’s value proposition in a competitive market, says ICON’s Tanya Brinsden, Jessica Cherian and Beranger Lueza. Arknea’s Rahul Varshneya identifies the emerging systems set to drive change across the industry. Using cross-functional teams to develop a product’s value story.
Pharmaceuticalcompanies are traditionally more conservative with their approach to and incorporation of new technologies; however, prior to COVID, the industry had begun moving toward intersecting health and technology. The post Refining digital collaboration appeared first on.
How hybrid virtual engagement is accelerating oncology communication. pharmaphorum’s digital magazine Deep Dive provides objective, issue-driven views, analysis, high-level interviews and unique research for pharmaceuticalcompanies, biotech firms and the wider healthcare sector. Read Deep Dive: Oncology 2021 in full.
Medical writing refers to creating healthcare-related textual content that aims to improve doctor-patient communication and provide insights on industry topics. Medical writers must be outstanding communicators, capable of breaking down complex ideas for the public and healthcare professionals in a digestible way.
Improvements in the quality and flow of data between primary care, secondary care and the patient leads to an infinitely better overall level of communication,” says Parkes, “which in turn leads to more engaged and educated patients. “We About the interviewees. Dr Gareth Parkes is a consultant gastroenterologist at Barts Health NHS Trust.
Experts from Executive Insight discuss how a holistic, multi-stakeholder approach can help companies overcome access barriers at all stages. How to improve payer engagement with tailored value communication. Value can mean different things to different payers.
John Mack (PG): So, when I got laid off and as a consultant, I was working for a consulting company, helping them do websites for pharmaceuticalcompanies in the.com bust, you know, a lot of people got laid off. It wasn’t just pharmaceuticalcompanies and others. So I was kind of older at that time.
Putting together a quarter-billion dollar pharma company from ten mergers in four months is not for the faint-hearted – but that’s what biotech investment guru Francesco de Rubertis has achieved with his latest project Centessa. Focus on Rare: the invisible burden of rare diseases. Digitalising drug discovery.
Read on for key stories from this year’s Frontiers Health conference in Italy, unlocking the promise of patient support programmes in oncology, supercharging communications with modular content, and much more. Company profile: Vinehealth. Create, approve, deploy: supercharging communications with modular content.
New York Magazine , the New York Times and The Economist amongst many other news organisations knocked down their paywalls for COVID-19-related coverage to keep readers informed in a rapidly changing and often confusing environment. In Britain, the venerable BBC launched BBC Bitesize to help parents home-school children.
Vaccine R&D stagnation likely Although ACIP recommendations are separate from the US Food and Drug Administration (FDA)’s approvals, national immunisation recommendation provides a key pillar on which to guide pipeline development for a pharmaceuticalcompany. Can pharma tariffs “Make America Manufacture Again”?
He noted that these conflicts of interest continue to the current day, with ACIP members receiving substantial funding from pharmaceuticalcompanies. Can pharma tariffs “Make America Manufacture Again”? The health secretary pointed to historical evidence for this, including an investigation from over 20 years ago.
It feels like in the US, pharmaceuticalcompanies are capitalising on people’s frustration and desperation to lose weight.” I don’t understand why medication costs are so much higher in the US compared to Europe, though I’ve noticed prices can vary across European countries too,” said Helena. “It
More specifically, the Indian Pharmaceutical Alliance, an organisation representing the country’s largest pharmaceuticalcompanies, has urged the government to reduce import tariffs from the current 10% to zero for pharmaceutical imports from the US. Can pharma tariffs “Make America Manufacture Again”?
Katarina Zahedi, pharma analyst at GlobalData, comments: “These investments reflect a growing trend among pharmaceuticalcompanies to bolster domestic operations in response to geopolitical pressures and potential tariffs on imported pharmaceuticals.” Can pharma tariffs “Make America Manufacture Again”?
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content